This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.
Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.
Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
Measurable disease per RECIST 1.1
ECOG performance status ≤ 2
Inability to provide informed consent
Inability to obtain a (new) biopsy for molecular profiling
Pregnancy or breastfeeding.
Other active malignancies requiring therapy.
Radboud University Medical Center
Lead sponsor
Maastricht University
Collaborator
EU Horizon
Collaborator
Horizon Europe
Collaborator